Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.855 USD | -0.80% | +11.45% | -2.63% |
06-06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
06-05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.63% | 151M | |
+45.69% | 754B | |
+40.95% | 630B | |
-5.67% | 352B | |
+19.90% | 331B | |
+9.42% | 298B | |
+18.74% | 250B | |
+12.05% | 217B | |
-0.61% | 216B | |
+6.26% | 164B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-Mab Says Combination Treatment for Myelodysplastic Syndrome Showed Overall Response Rate of 86.7% in Phase 2 Trial